Guggenheim reiterates Biogen stock rating on Alzheimer’s drug data By Investing.com

Biogen’s Phase 2 CELIA study of diranersen showed slowing of clinical decline across all doses and maintained reductions in CSF tau and tau PET biomarkers over 18 months, though it missed its primary dose-response endpoint. Guggenheim reiterated a Buy and $260 target, while other firms also turned positive despite the mixed readout. The stock trades at $191.37, below Guggenheim’s target and InvestingPro’s fair value estimate of $258.41.

Analysis

BIIB is getting a classic “data disappointment, pipeline validation” setup: the market can look through a missed statistical construct if the biology is credible and the asset now has a clearer path to a registrational design. The key second-order effect is that tau remains one of the few Alzheimer’s mechanisms with a plausible disease-modifying narrative, so even a messy read-through can re-rate sentiment across adjacent neurodegeneration names with biomarker-driven programs.

The risk is timing and financing of conviction, not just science. A Phase 3 launch de-risks the story only if management can preserve optionality on dose and endpoint selection; if they overfit to the apparent low-dose signal, the market may punish the program again on execution rather than efficacy. Watch for a drift higher into full data disclosure, but expect the tape to become more binary once investors start modeling the registrational trial’s duration, sample size, and probability of placebo separation.

The bigger trade is that sentiment in BIIB may now be more sensitive to the rest of the pipeline than to this single readout. If the Alzheimer’s asset is tolerated as a “near miss with real biology,” then the market can start assigning more value to the rest of the franchise, especially any programs with near-term catalysts. Conversely, any setback in the next 1-2 readouts would remind investors that the stock still trades with a high implied probability of pipeline disappointment, making the rerating fragile.

Key Decisions for Investors

• Long BIIB on pullbacks over the next 1-3 weeks into full-data presentation; target a move toward the mid-$200s if management confirms Phase 3 design discipline. Keep a tight stop if the transcript suggests endpoint confusion or weak dose rationale.
• Buy BIIB call spreads expiring after the July data release to express upside while limiting premium burn; attractive if implied vol stays elevated but not euphoric.
• Pair BIIB long against a basket of higher-duration neuro/Alzheimer’s names with weaker biomarker credibility; this isolates the market’s willingness to reward real target engagement versus pure narrative.
• If BIIB rallies hard into the conference, fade part of the move with covered calls or a tactical trim: the next leg depends on Phase 3 specifics, and the gap between “interesting” and “registrationally compelling” is still material.